Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future. by Huycke, M. M. et al.
239 Vol. 4, No. 2, April–June 1998 Emerging Infectious Diseases
Synopses
The past few years have witnessed increasing
interest in enterococci. Until recently, these
ordinary bowel commensals languished as
misclassified streptococci, commonly perceived
“with the exception of endocarditis and rare cases
of meningitis … [as] not … a major cause of
serious infection” (1). In the last decade, however,
enterococci have become recognized as leading
causes of nosocomial bacteremia, surgical wound
infection, and urinary tract infection (2,3). Two
types of enterococci cause infections: 1) those
originating from patients’ native flora, which are
unlikely to possess resistance beyond that
intrinsic to the genus and are unlikely to be
spread from bed to bed, and 2) isolates that
possess multiple antibiotic resistance traits and
are capable of nosocomial transmission. The
therapeutic challenge of multiple-drug resistant
(MDR) enterococci—those strains with signifi-
cant resistance to two or more antibiotics, often
including, but not limited to, vancomycin—has
brought their role as important nosocomial
pathogens into sharper focus.
The accretion and spread of antibiotic
resistance determinants among enterococci, to the
point where some clinical isolates are resistant to
all standard therapies, highlight both the
vulnerability of our present armament as well as
the looming prospect of a “postantibiotic era” (4).
This review focuses on the magnitude and nature of
the problem posed by enterococci in general, and
MDR enterococci in particular. For many points,
only representative citations are provided.
Habitat and Microbiology
Enterococci normally inhabit the bowel. They
are found in the intestine of nearly all animals,
from cockroaches to humans. Enterococci are
readily recovered outdoors from vegetation and
surface water, probably because of contamination
by animal excrement or untreated sewage (5). In
humans, typical concentrations of enterococci in
stool are up to 108 CFU per gram (6). Although the
oral cavity and vaginal tract can become
colonized, enterococci are recovered from these
sites in fewer than 20% of cases. The
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predominant species inhabiting the intestine
varies. In Europe, the United States, and the Far
East, Enterococcus faecalis predominates in some
instances and E. faecium in others (6). Ecologic or
microbial factors promoting intestinal coloniza-
tion are obscure. Of 14 or more enterococcal
species (7), only E. faecalis and E. faecium
commonly colonize and infect humans in
detectable numbers. E. faecalis is isolated from
approximately 80% of human infections, and E.
faecium from most of the rest. Infections to other
enterococcal species are rare.
Enterococci are exceedingly hardy. They
tolerate a wide variety of growth conditions,
including temperatures of 10°C to 45°C, and
hypotonic, hypertonic, acidic, or alkaline environ-
ments. Sodium azide and concentrated bile salts,
which inhibit or kill most microorganisms, are
tolerated by enterococci and used as selective
agents in agar-based media. As facultative
organisms, enterococci grow under reduced or
oxygenated conditions. Enterococci are usually
considered strict fermenters because they lack a
Kreb’s cycle and respiratory chain (8). E. faecalis
is an exception since exogenous hemin can be
used to produce d, b, and o type cytochromes
(9,10). In a survey of 134 enterococci and related
streptococci, only E. faecalis and Lactococcus
lactis expressed cytochrome-like respiration (11).
Cytochromes provide a growth advantage to E.
faecalis during aerobic growth (9). E. faecalis
cytochromes are only expressed under aerobic
conditions in the presence of exogenous hemin
(9,10,12) and, therefore, may promote the
colonization of inappropriate sites.
Enterococci are intrinsically resistant to
many antibiotics. Unlike acquired resistance and
virulence traits, which are usually transposon or
plasmid encoded, intrinsic resistance is based in
chromosomal genes, which typically are
nontransferrable. Penicillin, ampicillin,
piperacillin, imipenem, and vancomycin are
among the few antibiotics that show consistent
inhibitory, but not bactericidal, activity against
E. faecalis. E. faecium are less susceptible to ß-
lactam antibiotics than E. faecalis because the
penicillin-binding proteins of the former have
markedly lower affinities for the antibiotics (13).
The first reports of strains highly resistant to
penicillin began to appear in the 1980s (14,15).
Enterococci often acquire antibiotic resis-
tance through exchange of resistance-encoding
genes carried on conjugative transposons,
pheromone-responsive plasmids, and other broad-
host-range plasmids (6). The past two decades
have witnessed the rapid emergence of MDR
enterococci. High-level gentamicin resistance
occurred in 1979 (16) and was quickly followed by
numerous reports of nosocomial infection in the
1980s (17). Simultaneously, sporadic outbreaks
of nosocomial E. faecalis and E. faecium infection
appeared with penicillin resistance due to ß-
lactamase production (18); however, such isolates
remain rare. Finally, MDR enterococci that had
lost susceptibility to vancomycin were reported in
Europe (19,20) and the United States (21).
Among several phenotypes for vancomycin-
resistant enterococci, VanA (resistance to
vancomycin and teicoplanin) and VanB (resis-
tance to vancomycin alone) are most common
(22). In the United States, VanA and VanB
account for approximately 60% and 40% of
vancomycin-resistant enterococci (VRE) isolates,
respectively (23). Inducible genes encoding these
phenotypes alter cell wall synthesis and render
strains resistant to glycopeptides (22).
VanA and VanB types of resistance are
primarily found among enterococci isolated from
clinical, veterinary, and food specimens (24), but
not other common intestinal or environmental
bacteria. In the laboratory, however, these genes
can be transferred from enterococci to other
bacteria (22). For example, Staphylococcus
aureus has been rendered vancomycin-resistant
through apparent transfer of resistance from E.
faecalis on the surface of membrane filters and on
the skin of hairless obese mice (25), which
indicates that there is no biologic barrier to the
emergence of vancomycin-resistant S. aureus.
Clinical isolates of highly vancomycin-resistant
S. aureus have yet to be identified, although
strains with reduced susceptibility to vancomycin
have appeared (26). The mechanism of resistance
for these strains remains undetermined but does
not appear to involve genes associated with VanA
or VanB phenotypes.
Epidemiology
Enterococci account for approximately 110,000
urinary tract infections, 25,000 cases of bacter-
emia, 40,000 wound infections, and 1,100 cases of
endocarditis annually in the United States
(2,27,28). Most infections occur in hospitals.
Although several studies have suggested an
increase in nosocomial infection rates for
enterococci in recent years, National Nosocomial241 Vol. 4, No. 2, April–June 1998 Emerging Infectious Diseases
Synopses
Infections Surveillance system data show little
change in the percentage of enterococcal
bloodstream (12% vs. 7%), surgical site (15% vs.
11%), and urinary tract (14% vs. 14%) infections
over the past 2 decades (3,29). Adequate
surveillance data prior to 1980 are not available.
Enterococcal infection deaths have also been
difficult to ascertain because severe comorbid
illnesses are common; however, enterococcal sepsis
is implicated in 7% to 50% of fatal cases (6). Several
case-control and historical cohort studies show that
death risk associated with antibiotic-resistant
enterococcal bacteremia is severalfold higher than
death risk associated with susceptible enterococcal
bacteremia (30). This trend will likely increase as
MDR isolates become more prevalent.
Colonization and infection with MDR entero-
cocci occur worldwide. Early reports showed that
in the United States, the percentage of
nosocomial infections caused by VRE increased
more than 20-fold (from 0.3% to 7.9%) between
1989 and 1993, indicating rapid dissemination.
New database technologies, such as The
Surveillance Network (TSN) Database-USA, now
permit the assessment of resistance profiles
according to species. TSN Database electroni-
cally collects and compiles data daily from more
than 100 U.S. clinical laboratories, identifies
potential laboratory testing errors, and detects
emergence of resistance profiles and mechanisms
that pose a public health threat (e.g., vancomy-
cin-resistant staphylococci).
Data collected by the TSN Database between
1995 and September 1, 1997 were analyzed to
determine whether the earlier increase in
vancomycin resistance was unique to vancomy-
cin, whether it represented a continuing trend,
and whether speciation is quantifiably important
in analyzing this trend. E. faecalis resistance to
ampicillin and vancomycin is uncommon (Figure
1); little change in resistance prevalence occurred
from 1995 to 1997. In contrast, E. faecium
vancomycin and ampicillin resistance increased
alarmingly. In 1997, 771 (52%) of 1,482 of E.
faecium isolates exhibited vancomycin resis-
tance, and 1,220 (83%) of 1,474 isolates exhibited
ampicillin resistance (Figure 1). E. faecium
resistance notwithstanding, E. faecalis remained
by far the most commonly encountered of the two
enterococcal species in TSN Database. E. faecalis
to E. faecium total isolates were approximately
4:1 (Figure 1), blood isolates 3:1, and urine
isolates 5:1. This observation underscores
important differences in the survival strategies
and likelihood of therapeutic success, critical
factors usually obscured by lumping the
organisms together as Enterococcus species or
enterococci. Widespread emergence and dissemi-
nation of ampicillin and vancomycin resistance in
E. faecalis would significantly confound the
current therapeutic dilemma. There is little
reason to suspect that vancomycin and ampicillin
resistances only provide selective advantage for
the species faecium and not faecalis. The relative
absence of these resistances in E. faecalis may
simply reflect a momentary lack of penetrance
and equilibration of the traits. Because of these
important differences between the two species,
meaningful surveillance of enterococcal resis-
tance must include species identification.
Although exact modes of nosocomial trans-
mission for MDR enterococci are difficult to
prove, molecular microbiologic and epidemiologic
evidence strongly suggest spread between
patients, probably on the hands of health-care
providers or medical devices, and between
hospitals by patients with prolonged intestinal
Figure 1. Epidemiology of enterococcal infection based
on 15,203 susceptibility results obtained by The
Surveillance Network (TSN) Database-USA, 1995 to
Sep 1, 1997. The increase in total numbers between
1995 and 1996 represents additional reporting
centers coming on line. Numbers for 1997 represent
total collected for the partial year to Sep 1, 1997.242 Emerging Infectious Diseases Vol. 4, No. 2, April–June 1998
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colonization. At least 16 outbreaks of MDR
enterococci have been reported since 1989 (31);
all but two were due to E. faecium. This disparity,
particularly in view of the higher numbers of
clinical  E. faecalis isolates, may reflect a
reporting bias due to the novelty of the
combinations of resistance that occur in E.
faecium. When isolates from outbreaks of MDR
enterococci have been analyzed by genetic
fingerprints, more than half involve clonally
related isolates (18,32).
Prior treatment with antibiotics is common in
nearly all patients colonized or infected with
MDR enterococci (33-35). Clindamycin, cepha-
losporin, aztreonam, ciprofloxacin,
aminoglycoside, and metronidazole use is equally
or more often associated with colonization or
infection with MDR enterococci than vancomycin
use. Other risk factors include prolonged
hospitalization; high severity of illness score;
intraabdominal surgery; renal insufficiency;
enteral tube feedings; and exposure to specific
hospital units, nurses, or contaminated objects
and surfaces within patient-care areas.
Infection Control
Controlling the spread of MDR enterococci
among inpatients is difficult. We know relatively
little about the biology of enterococcal transmis-
sion or the specific microbial factors favoring
colonization by exogenous enterococcal strains.
Nevertheless, VRE infection control policies,
which could apply to MDR enterococci, were
recently published by the Hospital Infection
Control Practices Advisory Committee (36).
Control methods include routine screening for
vancomycin resistance among clinical isolates,
active surveillance for VRE in intensive care
units, contact isolation to minimize person-to-
person transmission, and vancomycin restriction.
These measures to limit VRE spread,
however, have failed on occasion (35). Not all
hospitals can or are willing to perform active
surveillance. Because more patients are typically
colonized with VRE (3% to 47%) than are infected
(35,37,38), and because intestinal colonization
can be prolonged, passive surveillance by routine
cultures allows colonized inpatients to go
unidentified and serve as point sources for
continued spread of VRE. Even if all colonized
inpatients are successfully identified, VRE may
be spread by health-care workers through either
inadequate hand washing (39) or through contact
with items such as bedrails, sinks, faucets, and
doorknobs (enterococci can persist for weeks on
environmental surfaces) (40). Decontamination
efforts must be rigorous.
The Hospital Infection Control Practices
Advisory Committee strongly recommended re-
stricting oral and parenteral vancomycin to control
VRE (36). However, limiting use of vancomycin
while ignoring widespread use of other broad
spectrum antibiotics likely will not lead to maximal
control of VRE or of MDR enterococci.
Antibiotics may promote colonization and
infection with MDR enterococci by at least two
mechanisms. First, many broad spectrum
antibiotics have little or no anti-enterococcal
activity, and administration commonly leads to
overgrowth of susceptible (or resistant) entero-
cocci at sites at risk for infection. Second, most
antibiotics substantially reduce the normal
resistance of the intestinal tract to colonization
by exogenous organisms (41). Colonization
resistance results primarily from the “limiting
action” of the normal anaerobic flora, and to a
lesser extent from an intact mucosa, gastric acid
secretion, intestinal motility, and intestinal-
associated immunity (41). Antibiotic-induced
alterations in the protective flora of the intestine
provide large footholds for colonization with
exogenous pathogens such as MDR enterococci
(41). Antibiotic restriction programs would be
more effective if they included prudent prescrib-
ing of all antibiotics, not just single agents such as
vancomycin. This approach substantially de-
creased intestinal colonization with VRE in one
hospital pharmacy that restricted vancomycin,
cefotaxime, and clindamycin (42).
At a minimum, a successful program for control
of MDR enterococci requires effective passive and
active surveillance to identify colonized and
infected patients, absolute adherence to contact
isolation by health-care workers, rigorous decon-
tamination of patient-contact areas and judicious
use or restriction of vancomycin and other broad
spectrum antibiotics.
Therapeutic Approaches
Suitable antibiotics often are not available to
treat MDR enterococcal infections, e.g., en-
docarditis or bacteremia, in the presence of
neutropenia. Combinations of penicillin with
vancomycin, ciprofloxacin with ampicillin, or
novobiocin with doxycycline, among others, have
been used (43) but can be unpredictable and243 Vol. 4, No. 2, April–June 1998 Emerging Infectious Diseases
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remain clinically unproven. In one report
chloramphenicol successfully treated chloram-
phenicol-susceptible infections (44), but these
findings await confirmation in controlled trials.
Promising new antibiotics for MDR entero-
coccal infection under investigation include
fluoroquinolones, streptogramins, oxazolidinones,
semisynthetic glycopeptides, and glycylcyclines.
Clinafloxacin, a fluoroquinolone with improved
potency against enterococci compared with
ciprofloxacin, has excellent activity against VRE,
appears bactericidal in vitro, and has been
effective in treatment of enterococcal infections
in a murine model (45). Although single-step
resistance to clinafloxacin could not be detected
in vitro, multistep resistance is readily achieved.
Should this agent gain approval for treatment of
enterococcal infections, selection for resistance
may limit its effectiveness.
Quinupristin/dalfopristin (Synercid) is a
combination of streptogramins A and B that
inhibits protein synthesis and has a narrower
spectrum of activity against enterococci than
clinafloxacin (46). Many, but not all, E. faecium
isolates with VanA and VanB phenotypes are
susceptible (47); however, E. faecalis is uniformly
resistant, and superinfection has been reported
during therapy (48). In addition, quinupristin/
dalfopristin is bacteriostatic only, potentially
allowing emergence of resistance (49). For these
reasons the drug may have only a limited role in
treating MDR enterococcal infections. Novel
oxazolidinones and glycylcyclines have also shown
potent activity against enterococci, including MDR
enterococci (50,51), but await further testing.
The substantial drawback of the broad
spectrum approach is that the more organisms
affected (both protective commensals as well as
pathogens), the more opportunities for resistance
to evolve. Broad spectrum antibiotics permit
empiric therapy in the absence of a specific
diagnosis and generate a more substantial return
on investment in the short term. However, broad
spectrum antibiotics affect not only disease-
causing organisms but also commensals present
in numbers large enough to generate resistance
by otherwise rare mutations or genetic exchange
events. As long as market forces favor
development of broad spectrum therapeutics, a
cycle of drug introduction followed by emergence
of resistance undoubtedly will continue.
Targeted Therapeutics
In contrast to the historical reliance on broad
spectrum antibiotic therapy, the continuing
development and introduction of rapid diagnostic
techniques (52) may allow a more focused
approach to infectious disease therapy. Any of the
myriad microbial-host interactions that subvert
the host response or damage tissues during an
infection represent potential therapeutic targets.
However, many key interactions in disease
pathogenesis are specific to the organism
involved—a characteristic that is both a strength
and a weakness. Because of the specificity of
these interactions, rapid and accurate diagnosis
is required. However, therapeutics aimed only at
interaction between host and a specific pathogen
should leave the diverse commensal flora
essentially unaffected. As a result, the targeted
population would be restricted to the relatively
small numbers of disease-producing bacteria and
would not likely reach the numbers or diversity
required to make development of resistance a
statistical probability.
The current spectrum of approaches to
identify new antiinfective compounds has two
extremes: 1) screening vast libraries of com-
pounds to identify substances that by chance
inhibit a microbial property and 2) detailed study
of interactions between host and parasite to
identify critical events leading to host tissue
damage or compromise (53).
With a long-term view toward new therapeu-
tic approaches as well as optimal use of existing
therapies, we and others have begun examining
in detail the interactions between enterococci and
host (6). A major obstacle is that enterococci also
form part of the commensal or autochthonous
flora; as such, they are nearly devoid of traits
traditionally associated with overt pathogens
and have subtle interactions with the host. Using
inocula with as few as 10 organisms, we have
developed sensitive biologic systems for examin-
ing the host-parasite interactions (54).
Although E. faecium strains are resistant to
vancomycin and ampicillin more often than E.
faecalis strains, the relative proportion of
infections caused by these species has not
dramatically changed in recent years (Figure 1).
Since both organisms are frequently isolated
from the commensal flora, this bias suggests that
E. faecalis traits confer a greater degree of244 Emerging Infectious Diseases Vol. 4, No. 2, April–June 1998
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intrinsic virulence, for example, cytolysin
production, pheromone-responsive plasmid trans-
fer (and accompanying production of aggregation
substance), extracellular superoxide production,
and a newly identified surface protein tentatively
termed Esp (5,56,57) (Figure 2). These properties
provide logical points of departure for developing
new targeted therapeutic approaches to enterococ-
cal disease; examination of more subtle interactions
between  E. faecium and host will follow as an
understanding of enterococcal biology evolves.
Targeting the E. faecalis Cytolysin
Cytolysin is disproportionately expressed by E.
faecalis strains associated with disease (5,55,56).
This cytolysin causes rupture of a variety of target
membranes, including bacterial cells, erythrocytes,
and other mammalian cells, with activity observed
as a hemolytic zone on some types of blood agar.
Cytolysin contributes to the toxicity or lethality of
infection in several infection models and is
associated with a fivefold increased risk of sudden
death from nosocomial bacteremia (54,56-59).
Cytolysin also contributes to the appearance of
enterococci in a murine bacteremia model (Figure 3;
45,60), an observation consistent with the
disproportionate representation of cytolytic strains
among human blood isolates (56,62).
Beginning with E.W. Todd in 1934 (63) and
culminating in a recent study (64), the E. faecalis
cytolysin has now been characterized as a unique,
extensively modified bacterial toxin (Figure 4).
The cytolysin maturation pathway is ideally
designed for therapeutic targeting because the
two structural subunits are activated by an
extracellular protease, an event that is accessible
and potentially inhibitable by a novel therapeu-
tic. Moreover, the activator protease, CylA,
belongs to the subtilisin class of serine proteases
(64), whose structure-function relationships and
inhibitor design we are beginning to understand.
Investigations are in progress to design and test
inhibitors of extracellular cytolysin activation to
determine whether a reduction by several logs in
the levels of circulating enterococci can be
attained as would be predicted by the observed
behavior of cytolysin mutants (Figure 3).
An inhibitor of cytolysin activation, accompa-
nied by appropriate rapid diagnostics, would be of
potential value in treating bacteremia caused by
cytolytic strains of E. faecalis without affecting
commensal flora. Development of resistance
should be exceedingly improbable because of the
small number of bacteria targeted and because
unlike antibiotics, cytolysin inhibitors would not
act directly on the organism itself.
Figure 2. Virulence traits and their association with
enterococcal species.
Figure 3. Cytolysin favors the appearance of circulating
enterococci. In this experiment, 107 CFU of E. faecalis,
either cytolytic FA2-2(pAM714) (60) or noncytolytic
FA2-2(pAM771) (64), were intraperitoneally injected
(45) into groups of five BalbC mice. Viable bacteria in
liver, spleen, and the bloodstream were enumerated 48
hrs following injection, and significance assessed by
Student’s t-test. (P. Coburn, L.E. Hancock, and M.S.
Gilmore, in preparation).245 Vol. 4, No. 2, April–June 1998 Emerging Infectious Diseases
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Figure 4. Cytolysin is expressed and processed
through a complex maturation pathway (64). The
cytolysin precursors, CylLL and CylLS, are ribosomally
synthesized. The putative modification protein, CylM,
is required for the expression of CylLL and CylLS in an
activatable form, and the secreted forms, CylLL and
CylLS were recently shown to possess the amino acid
lanthionine as the result of posttranslational
modification (64). CylLL and CylLS both are secreted
by CylB (65), which is accompanied by an initial
proteolytic trimming event (64) converting each to
CylLL’ and CylLS’, respectively. Once secreted, CylLL’
and CylLS’ are both functionally inactive until six
amino acids are removed from each amino terminus.
This final step in maturation is catalyzed by CylA (64),
a subtilisin-type serine protease. Since this final
catalytic event is essential, occurs extracellularly, and
is catalyzed by a class of enzyme for which a
substantial body of structural information exists, it
represents an ideal therapeutic target. As shown in
Figure 3, inhibition of cytolysin by mutation (or
potentially by therapeutic intervention) results in a
reduction by several orders of magnitude in the
number of circulating organisms.
Other Enterococcal Targets
Several laboratories are using information on
the  E. faecalis genome and genomes of other
pathogens to identify therapeutic targets (66)
and facilitate studies on pathogenesis for the
remaining 60% of noncytolytic enterococcal
infections. The genome of an E. faecalis strain
that caused multiple hospital infections (56) was
sampled at high frequency by sequence analysis.
Several sequences appeared to have a role in
host-parasite interaction. The gene specifying
Esp encodes an apparent surface protein of
unusual repeating structure (67). Although a role
for this protein in enterococcal infection has yet to
be determined, its distribution among clinical
and commensal strains is tantalizing: 29 of 30
strains with this gene were recovered from
patients with bacteremia or endocarditis; one of
34 isolates obtained from healthy volunteers
possessed Esp. The core of this large protein
(inferred mass of 202 kDa) consists of a series of
82 amino acid repeats encoded by highly
conserved tandem 246 base pair repeats. Lack of
divergence in repeat sequences suggests that
recombination occurs at high frequency, perhaps
during infection. Moreover, the number of repeats
observed in homologous genes from different E.
faecalis isolates is 3 to 9 (67). This gene is flanked by
a sequence similar to the transposase of IS905.
None of 24 clinical or laboratory E. faecium isolates
had this gene (67; V. Shankar, G. Lindahl, and M.
Gilmore, unpub. data).
A second promising lead involves a series of
genes encoding products highly related to
enzymes involved in O-antigen synthesis in
gram-negative bacteria (68). Preliminary evi-
dence suggests that in E. faecalis these genes
contribute to cell wall carbohydrate synthesis
and that this carbohydrate relates to persistence
in vivo. A knockout in one of these genes results in
a strain with normal in vitro growth, but after
subcutaneous injection, the mutant was more
readily cleared than the wild type parental strain
(68). One of the genes studied was present in all
E. faecalis strains examined, whereas another
occurs only in E. faecalis strains that share a
periodate-susceptible epitope (68). Collectively,
these data indicate that enzymes for synthesis of
E. faecalis surface carbohydrates are important
for persistence in vivo and may represent a useful
therapeutic target. Taking a different approach,246 Emerging Infectious Diseases Vol. 4, No. 2, April–June 1998
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Arduino et al. (69,70) identified a protease-
resistant, periodate susceptible substance associ-
ated with some strains of E. faecium, but not E.
faecalis, which conferred resistane to phagocyto-
sis in vitro. The relationship between the
putative carbohydrate of E. faecalis under study
above and the inhibitory substance of E. faecium
remains to be determined. It may be found that
many enterococci produce such carbohydrates at
biologically significant levels in vivo, but only
some strains of E. faecium do so in vitro.
Finally, recent observations indicate that
nearly all E. faecalis strains, and only a few E.
faecium strains, generate substantial extracellular
superoxide.  When E. faecalis isolates from patients
with endocarditis and bacteremia were compared
with isolates from healthy volunteers (71), on
average, extracellular superoxide production was
60% higher among blood isolates than commensal
strains. These data raised several questions: Do E.
faecalis that produce larger amounts of extracellu-
lar superoxide possess greater metabolic flexibility,
facilitating adaptation to nonintestinal infection
sites? Does free radical production lead to host cell
damage, allowing release of normally sequestered
nutrients (e.g., hemin) that might promote
enhanced  E. faecalis growth through cytochrome
formation? Might antioxidants modulate coloniza-
tion or invasive infection? Answers to these
questions may provide new insights into the
transition from intestinal colonization to infection
and may suggest new preventive strategies.
Obstacles to Further Development
Although important insights into enterococ-
cal biology and pathogenesis are being gleaned
from a reverse genetic approach, a paucity of
information still exists on how enterococci
colonize the intestinal tract and cause infection.
For example, do E. faecalis or E. faecium colonize
the colon through specific interactions with
ligands on human epithelial cells or intestinal
mucin? Do MDR enterococci possess alternate
binding activities that enable them to colonize
the intestinal tract at new sites without
competing with the indigenous enterococci? Do
probiotics have a role in restoring colonization
resistance to an intestinal ecology altered by
broad spectrum antibiotics?
Is enough being done to combat the
emergence of highly resistant nosocomial patho-
gens? To effectively compete, industry remains
highly responsive to market opportunities.
Research in the public sector has been slow to
respond, and as a result, our understanding of the
biology of enterococcal infection is inadequate.
Reasons for the modest public sector response
include the following. 1) The emergence of
resistant enterococci coincided with a reduction
of public support for non-AIDS related infectious
disease research. 2) The pathogenesis of
nosocomial infection deviates from paradigms
established for obligate pathogens. 3) The
research infrastructure is relatively small
because of the low importance traditionally
attached to enterococci as etiologic agents of
human disease and the deemphasis on antibiotic
resistance research in the 1980s.
Conclusions
Historically, substantial resources have been
invested in developing an in-depth understand-
ing of the molecular biology of model organisms.
During the 1960s and 1970s, when gram-
negative organisms were leading causes of
hospital- and community-acquired infections and
gram-positive organisms were typically sensitive
to existing antibiotics (72), a sizable investment
in gram-negative model organisms was appropri-
ate. However, with the emergence of gram-
positive organisms as leading causes of both
hospital- and community-acquired infection in
the 1990s, a reevaluation of public research
priorities is warranted.
Since antibiotic use became widespread 50
years ago, bacteria have steadily and routinely
developed resistance. Control of the emergence of
resistance will depend on new approaches to
prudent antibiotic use in hospitals and clinics,
based in part on improved surveillance for MDR
enterococci and on better systems to encourage staff
adherence to contact isolation procedures. Equally
important will be development of new drugs with
narrower spectra of activity aimed at known and
potentially new targets and the evolution of market
conditions that favor their use.
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